Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.

MLA

Wolf, Christian, et al. “Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.” PLoS ONE, vol. 8, no. 3, Mar. 2013, pp. 1–9. EBSCOhost, https://doi.org/10.1371/journal.pone.0058438.

APA

Wolf, C., Sidhu, J., Otoul, C., Morris, D. L., Cnops, J., Taubel, J., & Bennett, B. (2013). Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study. PLoS ONE, 8(3), 1–9. https://doi.org/10.1371/journal.pone.0058438

Chicago

Wolf, Christian, Jagdev Sidhu, Christian Otoul, Dexter L. Morris, Jennifer Cnops, Jorg Taubel, and Barbara Bennett. 2013. “Pharmacodynamic Consequences of Administration of VLA-4 Antagonist CDP323 to Multiple Sclerosis Subjects: A Randomized, Double-Blind Phase 1/2 Study.” PLoS ONE 8 (3): 1–9. doi:10.1371/journal.pone.0058438.